Haemonetics Co. Expected to Post Q1 2025 Earnings of $0.94 Per Share (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research raised their Q1 2025 earnings estimates for Haemonetics in a report issued on Thursday, March 28th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $0.94 per share for the quarter, up from their previous estimate of $0.93. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.08 EPS, FY2025 earnings at $4.12 EPS, Q1 2026 earnings at $1.19 EPS and FY2026 earnings at $4.77 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter in the previous year, the firm posted $0.85 earnings per share. Haemonetics’s revenue for the quarter was up 10.1% on a year-over-year basis.

HAE has been the topic of a number of other research reports. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Barrington Research reissued an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research report on Tuesday, February 13th. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th.

Haemonetics Stock Performance

Shares of HAE opened at $85.35 on Friday. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $4.33 billion, a P/E ratio of 34.70, a price-to-earnings-growth ratio of 2.16 and a beta of 0.34. The firm’s fifty day simple moving average is $77.28 and its two-hundred day simple moving average is $83.28. Haemonetics has a 12 month low of $70.74 and a 12 month high of $95.26.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in Haemonetics by 21.5% in the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock valued at $389,776,000 after buying an additional 1,091,484 shares during the last quarter. Capital Research Global Investors increased its stake in Haemonetics by 166.1% in the 1st quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier’s stock valued at $344,676,000 after buying an additional 3,402,873 shares during the last quarter. Vanguard Group Inc. increased its stake in Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after buying an additional 25,451 shares during the last quarter. Geode Capital Management LLC increased its stake in Haemonetics by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 991,418 shares of the medical instruments supplier’s stock valued at $84,409,000 after buying an additional 47,696 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Haemonetics by 7.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock valued at $70,697,000 after buying an additional 59,670 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.